ab56342 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab56342 は 6 報の論文で使用されています。

  • Vázquez R  et al. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget 8:7598-7613 (2017). WB . PubMed: 27935867
  • Tanaka M  et al. Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12:1089-1096 (2016). WB . PubMed: 27775715
  • Boi M  et al. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget 7:79637-79653 (2016). WB . PubMed: 27793034
  • Coudé MM  et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 6:17698-712 (2015). WB . PubMed: 25989842
  • Thompson CM  et al. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol 15:31 (2015). WB . PubMed: 25981500
  • Boi M  et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clin Cancer Res 21:1628-38 (2015). PubMed: 25623213

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録